Zoetis Inc. $ZTS Shares Sold by Caisse DE Depot ET Placement DU Quebec

Key Points

• Caisse DE Depot ET Placement DU Quebec sold 209,519 shares of Zoetis Inc., reducing its stake by 94.8% to 11,565 shares, valued at approximately $1.9 million.
• Several institutional investors have increased their holdings in Zoetis, with Portside Wealth Group LLC raising its stake by 24.7% and Tandem Investment Advisors Inc. increasing its holdings by over 100%.
• Zoetis reported a quarterly revenue of $2.46 billion and earnings of $1.76 per share, surpassing analysts' estimates, while forecasting earnings per share of $6.300-6.400 for FY 2025.

Caisse DE Depot ET Placement DU Quebec reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 94.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,565 shares of the company's stock after selling 209,519 shares during the quarter. Caisse DE Depot ET Placement DU Quebec's holdings in Zoetis were worth $1,904,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Portside Wealth Group LLC grew its holdings in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after purchasing an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. grew its holdings in shares of Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after purchasing an additional 198,089 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in Zoetis by 31.2% in the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after buying an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new stake in Zoetis in the first quarter worth $380,000. Finally, Sage Rhino Capital LLC lifted its position in Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after buying an additional 3,791 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS traded down $3.64 during trading hours on Tuesday, reaching $152.76. The stock had a trading volume of 2,177,534 shares, compared to its average volume of 3,067,273. The stock has a fifty day moving average of $153.49 and a 200 day moving average of $157.85. The stock has a market cap of $67.70 billion, a P/E ratio of 26.29, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the firm posted $1.56 EPS. The business's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.